• Janssen Pharmaceutica NV, of Beerse, Belgium, part of Johnson & Johnson, reported results of the PALMFlexS study. Data showed flexible maintenance dosing with Xeplion (paliperidone palmitate) was associated with a clinically relevant treatment response, and was well tolerated in both acute and non-acute patients with schizophrenia.